Navigation Links
The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness
Date:12/1/2008

KVISTGARD, Denmark, December 1 /PRNewswire-FirstCall/ -- Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Department of National Defence, has awarded a contract to Bavarian Nordic for the delivery of IMVAMUNE(R).

The Canadian authorities intend to use IMVAMUNE(R) as part of the country's bio-preparedness programme.

The contract provides for the delivery of 20,000 doses of IMVAMUNE(R) and payment for the application process to support the use of IMVAMUNE(R) in an emergency under the Canadian Government's Special Access Programme. The delivery will take place in 2009.

The contract also provides for the optional purchase of an additional 180,000 doses of IMVAMUNE(R) as well as payment for investigating the requirements for obtaining a licensure of the vaccine in Canada. Hereby, the Government of Canada and Bavarian Nordic have entered into a long term contract.

The order does not change Bavarian Nordic's previously announced financial guidance for 2008.

Smallpox and the need for a new vaccine

Smallpox is the most dangerous infectious disease ever faced by mankind. Hundreds of millions of people have died from the disease. Today, the smallpox threat may be encountered in various ways: bio-terrorism, synthetically manufactured viruses and outbreak from controlled smallpox stocks.

The old, conventional smallpox vaccines which have been stockpiled around the world are not suited to current needs. They are not safe and may cause severe side effects, even death. These vaccines cannot be given to people who are immune compromised, which constitute approx. 25 % of the population.

IMVAMUNE(R), Bavarian Nordic's new, third generation smallpox vaccine, offers a number of unique advantages compared to the old vaccines. The superior safety profile of IMVAMUNE(R) makes it suitable for vaccination of those with compromised immunity. Furthermore, the vaccine is easier to administer and it protects faster than the old vaccines, which is convenient for use in the general population in the case of an emergency.

According to Anders Hedegaard, President & CEO of Bavarian Nordic, "With the Canadian contract, yet another nation recognizes IMVAMUNE(R) as an essential part of the its smallpox preparedness. Furthermore Bavarian Nordic has just received a small follow-up order with the same Asian country under the same contractual framework as in March. This further demonstrates that countries are increasingly focused on building and retaining an optimum biological preparedness against smallpox, the world's most feared and dangerous infectious disease. With IMVAMUNE(R) these countries have gained access to the most innovative smallpox vaccine available."

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN(R) is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the U.S. government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
3. Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
4. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
5. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
8. Albemarle Optimizes Smallpox Drug Candidate for SIGA
9. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)... LINCOLNSHIRE, Ill. , July 11, 2017 /PRNewswire/ ... hematology and urinalysis diagnostic testing equipment as well ... latest innovation: a way to make quality assurance ... control processes. "Sysmex is well known for the ... SM Quality Monitor elevates quality assurance processes ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
Breaking Medicine Technology:
(Date:7/26/2017)... BC (PRWEB) , ... July 26, 2017 , ... ... (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of ... the period from April 1, 2017 to June 30, 2017. Iso International LLC ...
(Date:7/26/2017)... ... 2017 , ... Wendy M. Musielak, a partner at the Andrew Cores Family Law ... Association’s third Vice President earlier this year. She will serve the membership in this capacity ... President, in accordance with the organization’s by-laws. , Musielak joined the Andrew ...
(Date:7/26/2017)... ... , ... The number of adults 65 years or older is expected to ... control in the population are not well described. In a study published in The ... of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified factors associated ...
(Date:7/25/2017)... PALM SPRINGS, California (PRWEB) , ... July 25, 2017 , ... ... don't involve cranking up the air conditioner — think homemade gourmet ice cream, sparkling ... up inside a gift shop featuring fun mugs, journals, and other must-have knick knacks. ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist and ... provide the Pharmacist eCare Plan to Computer-Rx pharmacies through the STRAND ... ability to develop the Pharmacist eCare Plan, a shared document detailing a patient’s ...
Breaking Medicine News(10 mins):